Perrigo's Return To OTC Roots Restoring Investor Confidence
This article was originally published in The Pink Sheet
Executive Summary
The OTC drug, infant and adult nutritionals, Rx generic topicals and API manufacturer's share price has been up since it re-stated is historical revenues from Tysabri multiple sclerosis treatment royalties and reported interim 2017 first-quarter results. Perrigo will "fully concentrate on growing" OTC portfolio.